Genitope next year will likely submit its new personalized immunotherapy for follicular non-Hodgkin’s lymphoma for US Food and Drug Administration approval, Pharmacogenomics Reporter has learned.
A spokesperson representing Genitope told Pharmacogenomics Reporter last week that the company is “working closely with the FDA to prepare for a potential BLA filing in 2008” if clinical trials “are successful.”
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Try GenomeWeb Premium now.
You may already have institutional access!
Check if I qualify.
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
